Systemic inflammatory response induced by dacron graft and modulation by antimicrobial agents: experimental study.
BACKGROUND
The purpose of this work was to evaluate the effect that different antimicrobial agents and different forms of administering them would have over a systemic inflammatory response (SIR) induced by an intraperitoneally implanted collagen-coated Dacron graft.


METHODS
Thirty-six male Wistar rats were randomly allocated into six groups of 6 animals each: (I) control, (II) "sham," (III) graft but no antibiotic, (IV) graft plus systemic cefazolin, (V) graft plus locally applied gentamicin, and (VI) graft soaked in rifampicin. After 72 h, mesenteric lymph nodes, liver, kidney, and the implanted graft were sent to the microbiology laboratory and cultured for aerobic and anaerobic organisms in order to evaluate bacterial translocation. Serum cytokines (IL-1beta and TNF-alpha), myeloperoxidase activity in liver and kidney, and superoxide anion and superoxide dismutase activities in liver were also determined to evaluate the level of SIR.


RESULTS
Microbiologic and biochemical data indicated that intraperitoneal implantation of a collagen-coated Dacron graft induced a significant (P < 0.05) bacterial translocation and a high inflammatory response, both of which decreased significantly with antibiotic treatment regardless of the means of administration (P < 0.05).


CONCLUSIONS
The present experimental model shows that the antibiotics used, in different means of administration, reduce bacterial translocation and behave as modulators of the SIR induced by an intraperitoneal collagen-coated Dacron graft.
Lozano
Francisco S
FS
Surgical Investigations Unit, Department of Surgery, University Hospital, University of Salamanca, Spain. lozano@gugu.usal.es
García-Criado
Francisco J
FJ
Fresnadillo
Maria J
MJ
García
Enrique
E
García
José E
JE
Gómez-Alonso
Alberto
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use; D018407:Bacterial Physiological Phenomena / Q000187:drug effects; D002437:Cefazolin / Q000008:administration & dosage / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible; D003094:Collagen; D016207:Cytokines / Q000097:blood; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D010537:Peritoneum / Q000601:surgery*; D009195:Peroxidase / Q000378:metabolism; D011093:Polyethylene Terephthalates / Q000009:adverse effects*; D019736:Prostheses and Implants / Q000009:adverse effects*; D016459:Prosthesis-Related Infections / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D020099:Coated Materials, Biocompatible; D016207:Cytokines; D005839:Gentamicins; D011093:Polyethylene Terephthalates; D017382:Reactive Oxygen Species; D003094:Collagen; D009195:Peroxidase; D002437:Cefazolin; D012293:Rifampin